Awareness of HBV Functional Cure and Attitude Toward Related Clinical Trials Among Patients with Chronic Hepatitis B in China.
CHB
HBV functional cure
awareness
related clinical trials
Journal
Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
05
2023
accepted:
11
08
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
HBV functional cure is an optimal treatment goal for chronic hepatitis B (CHB) at present and numerous new drugs aiming for HBV functional cure are in development. We carried out an internet-based survey to understand the treatment status, unmet needs, awareness of HBV functional cure and attitude toward related clinical trials among CHB patients in China. An internet-based anonymous survey was conducted on CHB patients who reside in mainland China. Determinants of awareness and attitude were identified by logistic regression models. Of the 1220 CHB patients who completed the survey questionnaire, 11.1% (135/1220) were aware of HBV functional cure and 50.2% (612/1220) answered "definitely will" to participate in related clinical trials. Participants who knew their HBsAg level (HBsAg<1500 IU/mL: OR=3.03, 95% CI: 1.87-4.92; HBsAg≥1500 IU/mL: OR=2.57, 95% CI: 1.35-4.88), who expected to achieve HBsAg loss with treatment (OR=1.63, 95% CI: 1.07-2.50) and who were dissatisfied with current treatment due to the failure of achieving HBsAg loss (OR=1.67, 95% CI: 1.10-2.53) had better awareness of HBV functional cure. Participants who had HBsAg level less than 1500 IU/mL (OR=1.45, 95% CI: 1.05-1.99), treatment with pegylated interferon alpha with or without nucleos(t)ide (OR=1.68, 95% CI: 1.11-2.53) and better awareness of HBV functional cure (OR=1.62, 95% CI: 1.01-2.61) were more likely to say "definitely will" to participate in related clinical trials. Chinese CHB patients reported a low awareness of HBV functional cure. Although CHB patients in China reported a low rate of HBV functional cure awareness, they had a high acceptance of related clinical trials.
Identifiants
pubmed: 37636489
doi: 10.2147/PPA.S422916
pii: 422916
pmc: PMC10460183
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2063-2072Informations de copyright
© 2023 Duan et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Hepatol Int. 2016 Jan;10(1):1-98
pubmed: 26563120
J Hepatol. 2014 Oct;61(4):777-84
pubmed: 24915612
Lancet Gastroenterol Hepatol. 2022 Oct;7(10):932-942
pubmed: 35961359
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):796-829
pubmed: 35738290
J Viral Hepat. 2019 Oct;26(10):1146-1155
pubmed: 31087479
Hepatology. 2017 Oct;66(4):1296-1313
pubmed: 28762522
J Hepatol. 2020 Mar;72(3):539-557
pubmed: 31730789
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
Clin Gastroenterol Hepatol. 2021 Mar;19(3):463-472
pubmed: 32473348
J Clin Transl Hepatol. 2021 Jun 28;9(3):324-334
pubmed: 34221918
Hepatol Commun. 2023 Mar 24;7(4):
pubmed: 36972391
Hepatology. 2013 Aug;58(2):546-54
pubmed: 23504622
J Clin Transl Hepatol. 2018 Mar 28;6(1):25-34
pubmed: 29577029
J Hepatol. 2019 Mar;70(3):361-370
pubmed: 30367899
J Clin Transl Hepatol. 2017 Dec 28;5(4):297-318
pubmed: 29226097
Zhonghua Gan Zang Bing Za Zhi. 2022 Dec 20;30(12):1309-1331
pubmed: 36891718
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Liver Int. 2019 Oct;39(10):1868-1875
pubmed: 31136052